Friday, July 21, 2017 10:50:09 AM
Read my previous messages, taking into account that now it's confirmed we own 45% of Cyrcadia, Inc (US) and not the 40% stated there.
LLBO should be now at $0.004 and rise steadily in the coming months
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132386032
Sales and income projection (100K-10M units sold)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=131892724
The pros:
- LLBO stock price has increased 300% over the last three months.
- Cyrcadia has 3 patents in the US and other pending worldwide.
- The Detected movie will should be available in Internet after the summer.
- CISCO promotes Cyrcadia (iTbra) as an example of IoT/AI success but has not done a media campaign yet.
- FDA Class I approval can arrive at any time before the end of 2017.
- iTbra accuracy is higher than mamograms (87% vs. 83%)
- Cyrcadia Asia will start selling the iTbra + app by the beginning of 2018
- Cyrcadia Asia expects to screen over 3 millions women in one year.
- Cyrcadia, Inc (US) should start selling in the US by the beginning of 2018.
- Cyrcadia has hired the top healthcare advertising agency: Area 23
- The iTbra has a Class II clearance (tested on 500 patients) will be used to start selling the services through hospitals by the beginning of 2018.
- The iTbra will be sold later on as a product over-the-counter when receiving FDA Class I approval.
- The iTbra cost/year OTC should be around $200
- The iTbra cost/use though the hospital should be the same as a mamogram.
- The iTbra will help reduce 500,000 unnecessary biopsies in the US
- Cyrcadia claims to have 500,000 anticipated orders in 2017
Do your own due diligence before investing. But be sure that this is a real company with the support of CISCO. Some people are trying desperately to lower the price, but the fact is that anything below $0.004 is unrealistic according to the current official information.
Disclaimer: This information is only my opinion and should not be considered as an advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM